SNAP Technologies in the Clinical Pipeline
Over 5 clinical trials in 3 vaccine indications in 3 countries have been or are being carried out.
The POP BIO SNAP technology has been well validated in several human targets including the successful completion of Phase 3 clinical studies against SARS-CoV-2 (COVID-19) in collaboration with EuBiologics Co. Ltd., and ongoing clinical studies against respiratory syntactical virus (RSV) and herpes zoster virus (HZV) in collaboration with EuPOP Life Sciences.
The SNAP-Tech Driven EuCorVac-19
(SARS-CoV-2)
EuCorVac-19, is a protein-based vaccine consisting of Eubiologics protein antigen, EulMT licensed from Korea Institute of Science and Technology and the spontaneous-nanoliposome antigen particle (SNAP) technology of POP Biotechnologies. EuCorVac-19 met primary endpoints in a Phase 3 clinical study in the Philippines.
The SNAP-Tech Driven EuCorVac-19
(SARS-CoV-2)
EuCorVac-19, is a protein-based vaccine consisting of Eubiologics protein antigen, EulMT, in-licensed from Korea Institute of Science and Technology and the spontaneous-nanoliposome antigen particle (SNAP) technology of POP Biotechnologies. EuCorVac-19 has already proved its safety and efficacy in a Phase I/II clinical trial, the results of which were announced in December 2021. A Phase III clinical study is currently ongoing.
Phase I/II Trial
Clinically Validated
Part of the EuCorVac-19, a promising vaccine candidate targeting the novel coronavirus, was tested in a Phase I/II clinical trial involving 280 participants, and the results demonstrated significant potential for addressing the current global health crisis.
https://clinicaltrials.gov/study/NCT04783311
Phase III Trials
Officially Commenced
Phase III clinical trials, the final and most comprehensive stage of testing, have officially commenced.
CoPoP Production
Path for Human Testing
CoPoP is manufactured at a 2.5M dose scale in accordance with GMP standards. Additional components are also produced under GMP. CoPoP GLP toxicity report available.
Flexible Formulations
Versatile Solutions
The SNAP Vaccine Platform is compatible with other components, allowing for pre-mixing, two-vial mixing, and lyophilization. POP Biotechnologies is dedicated to providing versatile solutions for the development of innovative vaccines.
RSV and Shingles Treatments
Discover the latest advancements in our clinical pipeline, including treatments for RSV and Shingles. Our innovative approach is revolutionizing the field of infectious disease and cancer vaccines.
RSV Treatment
Learn about our groundbreaking RSV treatment.
Shingles Treatment
Explore our cutting-edge Shingles treatment.
Innovative Vaccines
Discover our groundbreaking vaccines for infectious diseases and cancer.
Ready to see what we can do together?
POP BIO holds the exclusive license for the SNAP patent portfolio. Excellent results have been independently obtained by more than five separate collaborators. SNAP liposomes, along with controls and simple assays for particle characterization, are ready to be shipped.